Rezvilutamide for metastatic hormone-sensitive prostate cancer

We read Weijie Gu and colleagues’ recent Article with great interest.1 Two interim analyses of their randomised phase 3 trial found that rezvilutamide plus androgen-deprivation therapy significantly improved radiographic progression-free survival and overall survival compared with bicalutamide plus androgen-deprivation therapy in patients with high-volume, metastatic hormone-sensitive prostate cancer, with a tolerable safety profile.